DIA

AMRI names new president for AMRI Europe

Wednesday, May 23, 2012 12:05 PM

AMRI, a global contract research and manufacturing organization, has appointed Ian Shott as president of AMRI Europe.

More... »


Ariosa launch Harmony Prenatal Test through LabCorp

Monday, May 14, 2012 01:54 PM

Ariosa Diagnostics, a molecular diagnostics company of San Jose, Calif., has signed a deal with Laboratory Corporation of America Holdings (LabCorp) and Integrated Genetics, to distribute and administer its HarmonyPrenatal Test in the U.S. and Canada.

More... »


Rx&D and Canadian government partner to strengthen research

Wednesday, March 21, 2012 09:39 AM

Canada’s Research Based Pharmaceutical Companies (Rx&D) and the Canadian Institutes of Health Research (CIHR) have renewed a partnership to strengthen clinical research done in Canada, announced Leona Aglukkaq, Minister of Health.

More... »

diaDexus highlights findings of two PLAC Lp-PLA(2) activity studies

Monday, March 19, 2012 11:49 AM

San Francisco–based diaDexus, a company focused on proprietary cardiovascular diagnostic products, reported highlights from two recent studies evaluating the clinical utility of its PLACR Test for Lp-PLA(2) activity.

More... »

Islet Sciences to acquire DiaKine Therapeutics

Friday, March 2, 2012 06:00 AM

Islet Sciences, a biotechnology company specializing in transplantation therapy for patients with diabetes, will acquire Charlottesville, Va.-based biopharmaceutical company DiaKine Therapeutics, which commercializes novel immune modulators for the treatment of diabetes and related complications.

More... »

Siemens partners with ViiV Healthcare and Tocagen

Thursday, February 9, 2012 08:12 AM

Siemens Healthcare Diagnostics has formed two new companion diagnostics partnerships with pharmaceutical companies ViiV Healthcare and Tocagen—marking a step for Siemens into the fast-growing segment of the in vitro diagnostics market.

More... »

Trovagene closes acquisition of CLIA laboratory assets

Wednesday, February 8, 2012 12:41 PM

Trovagene, a developer of trans-renal molecular diagnostics based in San Diego, Calif., has closed its acquisition of MultiGEN Diagnostics’ clinical laboratory assets. Trovagene previously announced the execution of the asset acquisition agreement on Jan. 6, 2012.

More... »

VGX-100 identified as potential therapy for improving corneal graft survival

Monday, January 30, 2012 02:40 PM

Circadian Technologies has published data in Investigative Ophthalmology & Visual Science (IOVS) showing that VEGF-C expression is markedly up-regulated in corneal graft rejection. The data also showed that VEGF-C blockade, through administration of Circadian's lead development candidate VGX-100, a human antibody against VEGF-C, significantly improved corneal graft survival in an animal model. The data indicates a new therapeutic opportunity for VGX-100 to improve corneal graft survival.

More... »

Joslin Diabetes Center to build translational center for the cure of diabetes

Thursday, January 26, 2012 12:48 PM

Boston-based Joslin Diabetes Center has received a $5 million grant from the Massachusetts Life Sciences Center. The grant is among the highest amounts ever received to support diabetes research in Massachusetts.

More... »

Aria Diagnostic launches study of non-invasive prenatal test

Wednesday, January 18, 2012 12:04 PM

As Down syndrome becomes an increasing concern, Aria Diagnostics is launching a comparative study of a non-invasive prenatal test to detect Trisomy 21 (associated with Down synrome) and the standard first-trimester screening test.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs